Nyxoah SA Discloses Going Concern Doubt, Material Weaknesses, and Escalating Patent Litigation in Annual Report

summarizeSummary

Nyxoah SA's annual report reveals substantial doubt about its ability to continue as a going concern, identifies material weaknesses in internal controls, and details escalating patent litigation, despite significant revenue growth.

check_boxKey Events

• Substantial Doubt About Going Concern

  Management has identified substantial doubt about the company's ability to continue as a going concern for at least the next twelve months, citing recurring losses and negative operating cash flows.

• Material Weaknesses in Internal Controls

  The company identified material weaknesses in its internal control over financial reporting as of December 31, 2025, related to insufficient accounting personnel and control documentation, with remediation efforts ongoing.

• Escalating Patent Litigation

  Nyxoah is involved in multiple patent infringement lawsuits with Inspire Medical Systems, Inc., including actions filed by both parties in the U.S. and Germany, and petitions for inter partes review.

• Increased Revenue and Losses in FY2025

  Revenue grew 122% to €10.0 million for the year ended December 31, 2025, driven by U.S. commercialization post-FDA approval, but net loss increased 52% to €90.1 million.

auto_awesomeAnalysis

Nyxoah SA's annual report for fiscal year 2025 reveals significant financial and operational challenges, including a 'substantial doubt' about its ability to continue as a going concern. This critical assessment stems from recurring losses and negative cash flows, despite a 122% increase in revenue to €10.0 million. The company also reported material weaknesses in its internal control over financial reporting, indicating potential issues with financial statement reliability. Furthermore, Nyxoah is engaged in extensive patent litigation with a key competitor, Inspire Medical Systems, Inc., involving multiple lawsuits and counterclaims, which introduces substantial legal and business risk. While recent financing efforts in late 2025, including a private placement and convertible bonds, are expected to extend the cash runway into the first quarter of 2027, the company still requires an additional €110 million to reach profitability. These disclosures highlight significant risks to the company's financial stability and operational integrity, overshadowing the positive impact of its Genio system's FDA approval in August 2025.